A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Called Enflonsia and developed by Merck & Co., the drug is an antibody intended to prevent illness from RSV, which can be particularly severe in young children.

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Merck won approval from the U.S. Food and Drug Administration for a shot that protects against RSV, the most common cause of hospitalization among infants, STAT notes.

Merck plans to make Enflonsia available for physicians and healthcare administrators to order in July 2025. Shipments will be delivered before the start of the 2025-2026 RSV season.

At the time, Merck said it planned to start taking orders in July and would deliver the doses in the U.S. this fall, ahead of the start of the RSV season.

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...

“I hate RSV,” said Edwards, who was not connected with the Merck trial. “Just to watch them struggle to breathe, and then they get scared, and then they cry, which of course makes the ...